Spine Top Stories Interim Analysis Of 2-Level BAGUERA® C IDE Study Meets Threshold For Non-Inferiority byTim AllenApril 16, 2025
Recon Top Stories JointMedica Announces Launch of IDE Study for Polymotion® Hip Resurfacing System byJosh SandbergApril 1, 2025
Spine Interim analysis of 1-level BAGUERA®C IDE study meets threshold for non-inferiority byJosh SandbergMarch 11, 2025
Regulatory Lipogems Announces Enrollment of the Final Patient in ARISE FDA Clinical Trials for Knee Osteoarthritis byJosh SandbergMarch 5, 2025
Recon Regulatory Top Stories Lipogems Announces Last Patient Enrolled in the U.S. FDA IDE Arise Study for the Treatment of Knee Osteoarthritis byTim AllenApril 10, 2024
Recon Regulatory Top Stories Lipogems Announces First Patient Enrolled in the Second U.S. FDA IDE Study for the Treatment of Knee Osteoarthritis byTim AllenApril 8, 2024
Biologics Regulatory U.S. FDA Grants Lipogems® Second IDE Approval For A Clinical Trial On The Treatment For Knee OA byJosh SandbergOctober 4, 2023
Extremities Top Stories Paragon 28®, Inc. Receives FDA Approval for IDE Feasibility Study of Its SMART Total Talus™ System for use in Conjunction with the APEX 3D™ Total Ankle Replacement System byJosh SandbergSeptember 11, 2023
Spine Synergy Spine Solutions Announces First Patient Enrolled in the Synergy Disc® 2-Level IDE Trial byJosh SandbergJune 29, 2023
Spine Top Stories Synergy Spine Solutions Completes Enrollment of 1-Level IDE Trial byJosh SandbergJune 5, 2023
